142 related articles for article (PubMed ID: 9921985)
21. Involvement of gp130/interleukin-6 receptor transducing component in interleukin-11 receptor.
Fourcin M; Chevalier S; Lebrun JJ; Kelly P; Pouplard A; Wijdenes J; Gascan H
Eur J Immunol; 1994 Jan; 24(1):277-80. PubMed ID: 8020567
[TBL] [Abstract][Full Text] [Related]
22. The altered apoptotic pathways in cisplatin and etoposide-resistant melanoma cells are drug specific.
Kissel CK; Schadendorf D; Röckmann H
Melanoma Res; 2006 Dec; 16(6):527-35. PubMed ID: 17119454
[TBL] [Abstract][Full Text] [Related]
23. Selection and characterization of a variant of human melanoma cell line, A375 resistant to growth inhibitory effects of oncostatin M (OM): coresistant to interleukin 6 (IL-6).
McDonald VL; Dick KO; Malik N; Shoyab M
Growth Factors; 1993; 9(3):167-75. PubMed ID: 8274294
[TBL] [Abstract][Full Text] [Related]
24. Inflammatory cytokines interleukin-6 and oncostatin m induce plasminogen activator inhibitor-1 in human adipose tissue.
Rega G; Kaun C; Weiss TW; Demyanets S; Zorn G; Kastl SP; Steiner S; Seidinger D; Kopp CW; Frey M; Roehle R; Maurer G; Huber K; Wojta J
Circulation; 2005 Apr; 111(15):1938-45. PubMed ID: 15837947
[TBL] [Abstract][Full Text] [Related]
25. Epitope peptides from interleukin-6 receptor which inhibit the growth of human myeloma cells.
Halimi H; Eisenstein M; Oh JW; Revel M; Chebath J
Eur Cytokine Netw; 1995; 6(3):135-43. PubMed ID: 8589270
[TBL] [Abstract][Full Text] [Related]
26. Regulation of interleukin-6-mediated PI3K activation and neuroendocrine differentiation by androgen signaling in prostate cancer LNCaP cells.
Xie S; Lin HK; Ni J; Yang L; Wang L; di Sant'Agnese PA; Chang C
Prostate; 2004 Jun; 60(1):61-7. PubMed ID: 15129430
[TBL] [Abstract][Full Text] [Related]
27. Significance of autologous interleukin-6 production in the HA22T/VGH cell model of hepatocellular carcinoma.
Labbozzetta M; Notarbartolo M; Poma P; Giannitrapani L; Cervello M; Montalto G; D'Alessandro N
Ann N Y Acad Sci; 2006 Nov; 1089():268-75. PubMed ID: 17261774
[TBL] [Abstract][Full Text] [Related]
28. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro.
Okamoto M; Lee C; Oyasu R
Cancer Res; 1997 Jan; 57(1):141-6. PubMed ID: 8988055
[TBL] [Abstract][Full Text] [Related]
29. Oncostatin M binds directly to gp130 and behaves as interleukin-6 antagonist on a cell line expressing gp130 but lacking functional oncostatin M receptors.
Sporeno E; Paonessa G; Salvati AL; Graziani R; Delmastro P; Ciliberto G; Toniatti C
J Biol Chem; 1994 Apr; 269(15):10991-5. PubMed ID: 8157624
[TBL] [Abstract][Full Text] [Related]
30. Interleukin-6 receptor signaling. I. gp80 and gp130 receptor interaction in the absence of interleukin-6.
Gaillard JP; Mani JC; Liautard J; Klein B; Brochier J
Eur Cytokine Netw; 1999 Mar; 10(1):43-8. PubMed ID: 10210772
[TBL] [Abstract][Full Text] [Related]
31. GP130/OSMR is the only LIF/IL-6 family receptor complex to promote osteoblast differentiation of calvaria progenitors.
Malaval L; Liu F; Vernallis AB; Aubin JE
J Cell Physiol; 2005 Aug; 204(2):585-93. PubMed ID: 15751050
[TBL] [Abstract][Full Text] [Related]
32. Prostaglandin E(2) stimulates prostatic intraepithelial neoplasia cell growth through activation of the interleukin-6/GP130/STAT-3 signaling pathway.
Liu XH; Kirschenbaum A; Lu M; Yao S; Klausner A; Preston C; Holland JF; Levine AC
Biochem Biophys Res Commun; 2002 Jan; 290(1):249-55. PubMed ID: 11779161
[TBL] [Abstract][Full Text] [Related]
33. Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice.
Smith PC; Keller ET
Prostate; 2001 Jun; 48(1):47-53. PubMed ID: 11391686
[TBL] [Abstract][Full Text] [Related]
34. Loss of drug-induced activation of the CD95 apoptotic pathway in a cisplatin-resistant testicular germ cell tumor cell line.
Spierings DC; de Vries EG; Vellenga E; de Jong S
Cell Death Differ; 2003 Jul; 10(7):808-22. PubMed ID: 12815464
[TBL] [Abstract][Full Text] [Related]
35. Comparative activity of Sant7 and anti-IL-6, IL-6R monoclonal antibodies in a murine model of B-cell lymphoma.
Campo S; Serlupi-Crescenzi O; Arseni B; Rossi S; Saggio I; Salone B; Cherubini G; Carminati P; De Santis R
Cytokine; 2005 Sep; 31(5):368-74. PubMed ID: 16061391
[TBL] [Abstract][Full Text] [Related]
36. Expression of interleukin-6, interleukin-6 receptor, and glycoprotein 130 correlates with good prognoses for patients with breast carcinoma.
Karczewska A; Nawrocki S; Breborowicz D; Filas V; Mackiewicz A
Cancer; 2000 May; 88(9):2061-71. PubMed ID: 10813718
[TBL] [Abstract][Full Text] [Related]
37. IL-6 antisense-mediated growth inhibition of a choriocarcinoma cell line: an intracellular autocrine growth mechanism.
Kong B; Isozaki T; Sasaki S
Gynecol Oncol; 1996 Oct; 63(1):78-84. PubMed ID: 8898173
[TBL] [Abstract][Full Text] [Related]
38. Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice.
Kim SJ; Uehara H; Karashima T; Shepherd DL; Killion JJ; Fidler IJ
Clin Cancer Res; 2003 Mar; 9(3):1200-10. PubMed ID: 12631626
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of gp130 signaling in breast cancer blocks constitutive activation of Stat3 and inhibits in vivo malignancy.
Selander KS; Li L; Watson L; Merrell M; Dahmen H; Heinrich PC; Müller-Newen G; Harris KW
Cancer Res; 2004 Oct; 64(19):6924-33. PubMed ID: 15466183
[TBL] [Abstract][Full Text] [Related]
40. Physician Education: The Erythropoietin Receptor and Signal Transduction.
Yoshimura A; Arai K
Oncologist; 1996; 1(5):337-339. PubMed ID: 10388012
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
